WATERLOO, Belgium, March 11, 2010 /PRNewswire/ --
- PRESILLION(TM) PLUS CoCr Coronary Stent Offers New Levels of Delivery, Support and Restoration for Arteriosclerotic Arteries
Cordis Corporation today announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances designed to gain easier access to distal lesions and help restore the artery's natural form.
"The new upgraded delivery system increases the speed of procedures with atraumatic delivery, increased pushability, and smoother withdrawal. We are very satisfied with the speed in which we were able to incorporate feedback from cardiologists into the new design," said Campbell Rogers MD, Global Head of R&D of Cordis Corporation.
The PRESILLION(TM) PLUS changes include a new hypotube for improved pushability in crossing calcified lesions and a redesigned semi-compliant balloon for precise stent deployment and decreased deflation time.
The PRESILLION(TM) PLUS stent is available in lengths from 8 to 33mm including a new 28mm addition and in diameters from 2.5 to 4.0mm.
The PIONIR study, designed to measure the safety and effectiveness of PRESILLION(TM) and PRESILLION(TM) PLUS, completed enrollment at 16 sites in Europe and Israel. The study, conducted by Medinol, includes 278 patients and will evaluate clinical performance through one year.
"Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done. The new PRESILLION(TM) PLUS further complements our portfolio with its technological advances. We will continue to deliver innovative new solutions that save lives and improve the quality of life for people around the world," said Staffan Ternstrom, President, Cordis Europe, Middle-East, Africa.
Cordis Corporation is the exclusive global distributor of PRESILLION(TM) PLUS, which is designed and manufactured by Medinol Ltd, Israel. PRESILLION (TM) PLUS is a trademark of Cordis Corporation.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at http://www.cordis.com.
Cordis Corporation signed an exclusive distribution agreement with Medinol in 2008 and will be distributing PRESILLION (TM) PLUS globally. Medinol is a stent innovation company that develops both stents and delivery systems through design innovation and advanced manufacturing technologies.
Advertisement
- PRESILLION(TM) PLUS CoCr Coronary Stent Offers New Levels of Delivery, Support and Restoration for Arteriosclerotic Arteries
Cordis Corporation today announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances designed to gain easier access to distal lesions and help restore the artery's natural form.
Advertisement
"The new upgraded delivery system increases the speed of procedures with atraumatic delivery, increased pushability, and smoother withdrawal. We are very satisfied with the speed in which we were able to incorporate feedback from cardiologists into the new design," said Campbell Rogers MD, Global Head of R&D of Cordis Corporation.
The PRESILLION(TM) PLUS changes include a new hypotube for improved pushability in crossing calcified lesions and a redesigned semi-compliant balloon for precise stent deployment and decreased deflation time.
The PRESILLION(TM) PLUS stent is available in lengths from 8 to 33mm including a new 28mm addition and in diameters from 2.5 to 4.0mm.
The PIONIR study, designed to measure the safety and effectiveness of PRESILLION(TM) and PRESILLION(TM) PLUS, completed enrollment at 16 sites in Europe and Israel. The study, conducted by Medinol, includes 278 patients and will evaluate clinical performance through one year.
"Our vision at Cordis is to transform cardiovascular care, a field in which incredible progress has been made over the last decade, but one in which much more remains to be done. The new PRESILLION(TM) PLUS further complements our portfolio with its technological advances. We will continue to deliver innovative new solutions that save lives and improve the quality of life for people around the world," said Staffan Ternstrom, President, Cordis Europe, Middle-East, Africa.
Cordis Corporation is the exclusive global distributor of PRESILLION(TM) PLUS, which is designed and manufactured by Medinol Ltd, Israel. PRESILLION (TM) PLUS is a trademark of Cordis Corporation.
About Cordis Corporation
Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in the development and manufacture of interventional vascular technology. Through the company's innovation, research and development, Cordis partners with interventional cardiologists worldwide to treat millions of patients who suffer from vascular disease. More information about Cordis Corporation can be found at http://www.cordis.com.
Cordis Corporation signed an exclusive distribution agreement with Medinol in 2008 and will be distributing PRESILLION (TM) PLUS globally. Medinol is a stent innovation company that develops both stents and delivery systems through design innovation and advanced manufacturing technologies.
Media Contacts: Isabella Sharp
APCO Worldwide
[email protected]
+44(0)20-7526-3632
+44(0)7813-307490
SOURCE Cordis Corporation